Alkindi - direct healthcare professional communication (DHPC)

hydrocortisone

About

This direct healthcare professional communication (DHPC) contains important information for healthcare professionals prescribing, dispensing or administering the medicine(s). It also includes a communication plan with details of intended recipients and the dissemination date.

Documents

Direct healthcare professional communication (DHPC): Risk of acute adrenal insufficiency when switching from crushed or compounded oral hydrocortisone formulations to Alkindi (hydrocortisone granules in capsules for opening)

Key facts

• Medicine name:
  Alkindi
• Active substance:
  hydrocortisone
• Therapeutic area (MeSH):
  Adrenal Insufficiency
• Regulatory outcome:
  Variation
• DHPC type:
  Safety signal
• Human ATC codes:
  H02AB09
• Dissemination date:
  04/02/2021